Anika Therapeutics (ANIK) Cash from Investing Activities (2010 - 2026)

Anika Therapeutics (ANIK) has 17 years of Cash from Investing Activities data on file, last reported at -$1.2 million in Q1 2026.

• On a quarterly basis, Cash from Investing Activities fell 174.1% year-over-year to -$1.2 million in Q1 2026; TTM through Mar 2026 was -$3.3 million, a 31.77% increase from a year earlier, with the FY2025 full-year figure at -$401000.0, up 95.19% from the prior year.
• Cash from Investing Activities for Q1 2026 stood at -$1.2 million, down from $198000.0 in the prior quarter.
• Over the last five years, Cash from Investing Activities for ANIK reached as high as $1.7 million in Q1 2025 and fell as low as -$3.4 million in Q2 2024.
• Historically, Cash from Investing Activities has averaged -$1.3 million across 5 years, with a median of -$1.5 million in 2023.
• Across the five-year window, Cash from Investing Activities plunged 176.47% in 2022 and jumped 192.48% in 2025, its largest moves.
• Year by year, Cash from Investing Activities stood at -$2.5 million in 2022, then advanced by 27.24% to -$1.8 million in 2023, then grew by 28.97% to -$1.3 million in 2024, then jumped by 115.15% to $198000.0 in 2025, then plunged by 725.76% to -$1.2 million in 2026.
• Per Business Quant data, the three most recent Cash from Investing Activities figures were -$1.2 million in Q1 2026, $198000.0 in Q4 2025, and -$1.7 million in Q3 2025.